Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
Investigative Ophthalmology & Visual Science|July 28, 2004
Severe retinal degeneration associated with disruption of semaphorin 4ADennis S Rice, Wenhu Huang, Holly A Jones, et al.Blood|March 17, 2012
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemiaAlireza Eghtedar, Srdan Verstovsek, Zeev Estrov, et al.Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifsJohn I Trujillo, Wei Huang, Robert O Hughes, et al.Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituentsGregory R Ott, Naoyuki Asakawa, Zhonghui Lu, et al.Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE)Gregory R Ott, Naoyuki Asakawa, Zhonghui Lu, et al.Journal for Immunotherapy of Cancer|March 22, 2019
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanomaGeoffrey T Gibney, Omid Hamid, Jose Lutzky, et al.Cancer Biology & Therapy|April 22, 2006
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumabXiangdong Liu, Jordan S Fridman, Qian Wang, et al.Bioorganic & Medicinal Chemistry Letters|February 1, 2008
Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)Gregory R Ott, Naoyuki Asakawa, Rui-Qin Liu, et al.Journal of Medicinal Chemistry|August 9, 2002
Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonistsGeorge V De Lucca, Ui T Kim, Curt Johnson, et al.Journal of Medicinal Chemistry|May 28, 2004
Sultam hydroxamates as novel matrix metalloproteinase inhibitorsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.Pageof 5